{"id":"W2498506084","doi":"10.1016/s2213-2600(16)30152-7","title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":1062,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung, and Blood Institute","keywords":"Medicine; Cyclophosphamide; Mycophenolate; Placebo; Interstitial lung disease; Clinical endpoint; Internal medicine; Mycophenolic acid; Scleroderma (fungus); Surgery; Gastroenterology; Randomized controlled trial; Lung; Chemotherapy; Transplantation; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08201599126809177,"score_gpt":0.3333444022781768,"score_spread":0.251328411010085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}